Beyond the Bony Bar: PHD2 Inhibition as Oxygen-Niche Engineering for Growth Plate Regeneration
Tissue Engineering Part B: Reviews · 18.11.2026
DOI: 10.1177/19373368261506871 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Tissue Engineering Part B: Reviews, online erschienen am 18.11.2026. Verfasst von Luh Gede Djatu Anggitadewi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics and Traumatology, Faculty of Medicine, Universitas Airlangga, Indonesia. Die Arbeit nennt 45 Literaturangaben.
Abstract (Originalsprache)
The physeal oxygen gradient—from resting to hypertrophic zone—is an active instructional signal governing chondrocyte zonal identity. Hypoxia-inducible factor-1α (HIF-1α), stabilized when prolyl hydroxylase domain-containing protein 2 (PHD2) is inactive, is indispensable for physeal chondrocyte survival and extracellular matrix synthesis. Current biomimetic scaffolds cannot recreate this niche in vivo : Host vascular ingrowth drives intrascaffold pO 2 out of the hypertrophic-zone range within days, extinguishing HIF-1α signaling regardless of scaffold design. We evaluate transient PHD2 inhibition via IOX-2 as a pharmacological oxygen-niche strategy—designated Pillar IV—for functional growth plate regeneration. A scoping review (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) of PubMed/MEDLINE, Embase, and Web of Science identified 22 studies through March 2025. A separate targeted update in September 2026 identified three further in vivo studies of pharmacological PHD inhibition in skeletal repair, not incorporated into the evidence map. These show IOX-2 active in adult bone repair, with an osteogenic or mixed effect, and deliverable from an implanted scaffold. Fifteen of the 22 records are primary studies and seven are narrative or scoping reviews; across that heterogeneous set the charted evidence is consistent, rather than quantitatively synthesized, in identifying PHD2 as a principal and pharmacologically tractable regulator of HIF signaling in chondrocytes and IOX-2 as a selective inhibitor (IC 50 PHD2 = 21–22 nM; 36-fold over PHD1, 8-fold over PHD3). Physeal evidence supports HIF-1α dependence, but direct evidence for pharmacological PHD2 inhibition in the injured physis is limited, and release of IOX-2 from PLGA microspheres has not been characterized in any published study. What is mapped here is a pharmacological rationale for transcriptional mimicry of the physeal oxygen niche, not an engineered niche already realized; Pillars I–III are unpublished design specifications, and whether the four are jointly sufficient is a hypothesis for testing.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Orthopedics and Traumatology, Faculty of Medicine, Universitas Airlangga, Indonesia.
- Department of Orthopedics and Traumatology, Dr. Soetomo General Academic Hospital, Indonesia.
- Cell and Tissue Bank-Regenerative Medicine Center, Dr. Soetomo General Academic Hospital, Indonesia.
ORCID-Profile: Luh Gede Djatu Anggitadewi, Lukas Widhiyanto, Tri Wahyu Martanto, Ferdiansyah Mahyudin, Komang Agung Irianto, Heri Suroto
Zitieren
APA
Anggitadewi, L. G. D., Widhiyanto, L., Martanto, T. W., Mahyudin, F., Irianto, K. A., & Suroto, H. (2026). Beyond the Bony Bar: PHD2 Inhibition as Oxygen-Niche Engineering for Growth Plate Regeneration. Tissue Engineering Part B: Reviews. https://doi.org/10.1177/19373368261506871
Vancouver
Anggitadewi LGD, Widhiyanto L, Martanto TW, Mahyudin F, Irianto KA, Suroto H. Beyond the Bony Bar: PHD2 Inhibition as Oxygen-Niche Engineering for Growth Plate Regeneration. Tissue Engineering Part B: Reviews. 2026. doi:10.1177/19373368261506871
BibTeX
@article{Anggitadewi2026,
author = {Anggitadewi, Luh Gede Djatu and Widhiyanto, Lukas and Martanto, Tri Wahyu and Mahyudin, Ferdiansyah and Irianto, Komang Agung and Suroto, Heri},
title = {Beyond the Bony Bar: PHD2 Inhibition as Oxygen-Niche Engineering for Growth Plate Regeneration},
journal = {Tissue Engineering Part B: Reviews},
year = {2026},
doi = {10.1177/19373368261506871}
}
EUVIMED